Changes in the incidence of cannabis-related disorders after the Cannabis Act and the COVID-19 pandemic in Québec, Canada
- PMID: 38870546
- DOI: 10.1016/j.drugpo.2024.104484
Changes in the incidence of cannabis-related disorders after the Cannabis Act and the COVID-19 pandemic in Québec, Canada
Abstract
Background: The Canadian Cannabis Act (CCA, implemented in October 2018) and the COVID-19 pandemic (April 2020) might have contributed to cannabis-related harms in Québec, known for its stringent cannabis legal framework. We explored changes in incidence rates of cannabis-related disorders (CRD) diagnoses associated with these events in Québec.
Methods: We utilized linked administrative health data to identify individuals aged 15 year+ newly diagnosed with CRD during hospitalizations, emergency, and outpatients clinics across Québec, from January 2010 and March 2022 (147 months). Interrupted time-series analyses (ITSA) assessed differences (as percentage changes) in sex- and age-standardized, and sex-stratified, monthly incidence rates (per 100,000 population) attributed to the CCA and the COVID-19 pandemic, compared to counterfactual scenarios where pre-events trends would continue unchanged.
Results: The overall monthly mean rates of incident diagnoses nearly doubled from the pre-CCA period (1.56 per 100,000 population) to the COVID-19 pandemic period (3.02 per 100,000 population). ITSA revealed no statistically significant level or slope changes between adjacent study periods, except for a decrease in the slope of incidence rates among males by 1.84 % (95 % CI -3.41 to -0.24) during the COVID-19 pandemic compared to the post-CCA period. During the post-CCA period, the trends of incidence rates in the general and male populations grew significantly by 1.22 % (95 % CI 0.08 to 2.35) and 1.44 % (0.04 to 2.84) per month, respectively. Similarly significant increases were observed for the general and female populations during the COVID-19 pandemic, with monthly rates rising by 1.43 % (95 % CI 0.75 to 2.12) and 1.75 % (95 % CI 0.13 to 3.37), respectively. These increases more than doubled pre-CCA rates.
Conclusions: The incidence rates of CRD diagnoses across Québec appears to have increased following the implementation of the CCA and during the COVID-19 pandemic. Our findings echo public health concerns regarding potential cannabis-related harms and are consistent with previous Canadian studies.
Keywords: Cannabis Act; Cannabis-related disorders; Interrupted time series; Quebec.
Copyright © 2024. Published by Elsevier B.V.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no conflict of interest.
Similar articles
-
Changes in prenatal cannabis-related diagnosed disorders after the Cannabis Act and the COVID-19 pandemic in Quebec, Canada.Addiction. 2024 Oct;119(10):1784-1791. doi: 10.1111/add.16564. Epub 2024 Jun 19. Addiction. 2024. PMID: 38898560
-
Assessing the impact of the COVID-19 pandemic on the mental health-related hospitalization rate of youth in Canada: an interrupted time series analysis.Health Promot Chronic Dis Prev Can. 2024 Oct;44(10):417-430. doi: 10.24095/hpcdp.44.9.02. Health Promot Chronic Dis Prev Can. 2024. PMID: 39388293 Free PMC article.
-
Changes in Cannabis-Attributable Hospitalizations Following Nonmedical Cannabis Legalization in Canada.JAMA Netw Open. 2023 Oct 2;6(10):e2336113. doi: 10.1001/jamanetworkopen.2023.36113. JAMA Netw Open. 2023. PMID: 37796504 Free PMC article.
-
The association between recreational cannabis legalization, commercialization and cannabis-attributable emergency department visits in Ontario, Canada: an interrupted time-series analysis.Addiction. 2022 Jul;117(7):1952-1960. doi: 10.1111/add.15834. Epub 2022 Feb 17. Addiction. 2022. PMID: 35170149
-
Changes in health harms due to cannabis following legalisation of non-medical cannabis in Canada in context of cannabis commercialisation: A scoping review.Drug Alcohol Rev. 2023 Feb;42(2):277-298. doi: 10.1111/dar.13546. Epub 2022 Sep 27. Drug Alcohol Rev. 2023. PMID: 36165188
Cited by
-
Prenatal cannabis exposure in the clinic and laboratory: What do we know and where do we need to go?Drug Alcohol Depend Rep. 2024 Sep 18;13:100282. doi: 10.1016/j.dadr.2024.100282. eCollection 2024 Dec. Drug Alcohol Depend Rep. 2024. PMID: 39430603 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous